Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7923182 | 0.78 | NOS1 (0.41) | NOS1NOS2CYP1A2CCR1RAB9A | |
| SCHEMBL31194844 | 0.78 | NOS1 (0.41) | NOS1NOS2CYP1A2CCR1RAB9A | |
| Hydrochloric Acid SCHEMBL23290959 | 0.77 | NOS1 (0.40) | NOS1NOS2CYP1A2CCR1RAB9A | |
| Hydrochloric Acid SCHEMBL29733327 | 0.77 | NOS1 (0.40) | NOS1NOS2CYP1A2CCR1RAB9A | |
| Ammonia Solution, Strong SCHEMBL17104360 | 0.77 | NOS1 (0.40) | NOS1NOS2CYP1A2CCR1RAB9A | |
| SCHEMBL15532841 | 0.75 | LMNA (0.42) | NOS1NOS2CYP1A2CCR1RAB9A | |
| SCHEMBL16896417 | 0.75 | IDO1 (0.36) | — | |
| SCHEMBL17250005 | 0.72 | NOS1 (0.37) | NOS1NOS2CYP1A2CCR1RAB9A | |
| SCHEMBL22382417 | 0.71 | TRPV4 (0.38) | KDM4E | |
| SCHEMBL31202592 | 0.71 | TRPV4 (0.38) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | NOS1 3474/4885NOS2 3245/4885CYP1A2 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.